W. Timothy Garvey, MD, a UAB professor, was awarded the Gerald Reaven Distinguished Leader in Insulin Resistance Award by the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease. Garvey, known for developing Cardiometabolic Disease Staging, helps clinicians assess risk for Type 2 diabetes and cardiovascular disease, guiding treatment and weight loss therapy decisions.

In 2021, Garvey led groundbreaking trials at UAB for semaglutide (Ozempic, Wegovy, Rybelsus), a drug that showed promise in treating diabetes, cardiovascular disease, osteoarthritis, and sleep apnea.

The award, named after Gerald Reaven, MD, who coined the term “Syndrome X” (now metabolic syndrome), honors Garvey’s decades of research in carbohydrate metabolism and insulin resistance.

Garvey’s career spans decades of work, including leading the UAB Diabetes Research Center, securing NIH and other funding, and shaping national guidelines for obesity and diabetes treatment.